Accenture and 1QBit have partnered with Biogen to develop a quantum-enabled molecular comparison application that could considerably improve advanced molecular design to accelerate drug discovery for complex neurological conditions like multiple sclerosis, Alzheimer’s, Lou Gehrig’s Disease and Parkinson’s.
A consortium featuring entities affiliated with GL Capital Management GP, Bank of China Group Investment (BOCGI), CDH Investments, Ascendent Capital Partners and Boying will acquire all the outstanding shares of SciClone Pharmaceuticals for $11.18 per share in cash.
Eleven Biotherapeutics signed a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to assess its late-clinical-stage fusion protein Vicinium (VB4-845) combined with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) to treat nonmuscle invasive bladder cancer (NMIBC).
Sevion Therapeutics has agreed to acquire Eloxx Pharmaceuticals, which is focused on developing therapeutics for genetic diseases caused by non-sense mutations.
Scientists at Florida’s The Scripps Research Institute (TSRI) have succeeded in modeling a key part of a virus that sickens several people in West Africa.
Taiwan-based OBI Pharma has agreed to acquire Threshold Pharmaceuticals' TH-3424, a novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).
Eisai and Charles River Laboratories International have agreed to extend their two-year collaboration in integrated drug discovery for another year.
AstraZeneca said that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA (ticagrelor) 90mg tablets as a precautionary measure.
Harpoon Therapeutics has secured $45m in Series B financing, which included new investors Arix Bioscience, New Leaf Venture Partners and Taiho Ventures along with existing investor MPM Capital.
Nektar Therapeutics and Takeda Pharmaceutical have entered into a research collaboration to explore the combination of the former’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from the cancer portfolio of Takeda.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.